Takara Bio Inc. Announces Unaudited Consolidated Earnings Results for the Full Year Ended March 31, 2019; Provides Earnings Guidance for the Six Months Ending September 30, 2019 and Full Year Ending March 31, 2020
May 14, 2019 at 02:00 am
Share
Takara Bio Inc. announced unaudited consolidated earnings results for the full year ended March 31, 2019. For the year, the company announced net sales of JPY 35,841 million compared to JPY 32,312 million a year ago. Operating income was JPY 5,463 million compared to JPY 3,555 million a year ago. Net income attributable to owners of the parent was JPY 3,657 million compared to JPY 2,335 million a year ago. Net income per share was JPY 30.38 compared to JPY 19.39 a year ago.
The company provided earnings guidance for the six months ending September 30, 2019 and full year ending March 31, 2020. For the six months ending September 30, 2019, the company expects net sales of JPY 17,129 million, operating income of JPY 2,917 million, net income attributable to owners of the parent was JPY 1,950 million and net income per share was JPY 16.20.
For the year ending March 31, 2020, the company expects net sales of JPY 36,000 million, operating income of JPY 6,200 million, net income attributable to owners of the parent was JPY 4,250 million and net income per share was JPY 35.29.
TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Takara Bio Inc. Announces Unaudited Consolidated Earnings Results for the Full Year Ended March 31, 2019; Provides Earnings Guidance for the Six Months Ending September 30, 2019 and Full Year Ending March 31, 2020
TAKARA BIO INC. 
